Contract 75A50325F80013
Alvogen, Inc. · Department Of Health And Human Services · June 29, 2025
Alvogen, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on June 29, 2025 for $227.68 million of work in pharmaceutical preparation manufacturing. Performance is in Pine Brook, NJ. This is a task or delivery order issued under parent IDIQ V797D70134. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 2, 2025.
Contract details
- PIID
- 75A50325F80013
- Parent IDIQ
- V797D70134
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Pine Brook, NJ
- First action
- June 29, 2025
- Latest action
- July 2, 2025
Description
OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS.
Modification timeline
-
July 2, 2025Mod P00001 · Other Administrative Action$227.68M
-
June 29, 2025Base award$227.68M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Merck Sharp & Dohme Llc | Department Of Health And Human Services | March 27, 2026 | $361.34M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50325F80013?
Contract 75A50325F80013 is a federal contract awarded to Alvogen, Inc. by Department Of Health And Human Services on June 29, 2025 for $227.68 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 1 time since the base award.
Who won contract 75A50325F80013?
Alvogen, Inc. won contract 75A50325F80013 from Department Of Health And Human Services.
How much is contract 75A50325F80013 worth?
Contract 75A50325F80013 has obligated $227.68 million to date.